Twitter-savvy physicians and researchers mull over the latest clinical results for Medtronic's renal denervation technology, calling for more common sense and less hype in treating hypertension.
Doctors and researchers at this year's EuroPCR conference look for answers in Medtronic's landmark SYMPLICITY HTN-3 clinical trial, which failed to find that renal denervation works against hypertension.
Amid the hand-wringing and back-pedaling surrounding renal denervation, some physicians are still looking for ways to use the technology to treat patients with hypertension.
St. Jude Medical says that its next-gen EnligHTN renal denervation system appears safe and effective in treating hypertension, but docs at this year's EuroPCR conference are calling for more robust clinical trials.
The marketing push for hypertension-treating renal denervation technology, clinical darling turned black sheep, has some doctors raising eyebrows at the EuroPCR conference in Paris this week.
Attendees at this year's EuroPCR conference in Paris cast a wary eye on medical device makers' efforts to promote renal denervation in treatment of hypertension, taking to Twitter to note and sometimes chide companies for putting "marketing before science."
U.S. and E.U. cardiologists call for a hard check on global sales of renal denervation technology in the wake of Medtronic's disappointing SYMPLICITY HTN-3 study.
MASSDEVICE ON CALL — A group of cardiologists is taking a hard stance against renal denervation, calling for medical device manufacturers to stop selling the technology as a treatment for hypertension.
More results from Medtronic's hypertension studies continue to muddle the outlook for renal denervation as medtech titans vie for prime listing for their transcatheter valves.
The American College of Cardiology's annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic's (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.
Medtronic's Symplicity renal denervation device for hypertension lowered blood pressure only slightly more than patients treated with drugs and a sham procedure, the company said today at the American College of Cardiology's annual conference.
Medtronic (NYSE:MDT) revealed the details today of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.